Karim Belhadj

Long-term outcome of patients in the LNH-98.5 trial, the first randomized study comparing rituximab-CHOP to standard CHOP chemotherapy in DLBCL patients: a study by the Groupe d'Etudes des Lymphomes de l'Adulte

Bertrand Coiffier, Catherine Thiéblemont, Éric Van Den Neste et al. · Blood · 2010 · 1.6K citations · Full text

Medicine, Hematology, Oncology +10

Lenalidomide, Bortezomib, and Dexamethasone with Transplantation for Myeloma

Michel Attal, Valérie Lauwers‐Cancès, Cyrille Hulin et al. · New England Journal of Medicine · 2017 · 1.2K citations · Full text

Medicine, Oncology, Pharmacotherapy +17

Bortezomib, thalidomide, and dexamethasone with or without daratumumab before and after autologous stem-cell transplantation for newly diagnosed multiple myeloma (CASSIOPEIA): a randomised, open-label, phase 3 study

Philippe Moreau, Michel Attal, Cyrille Hulin et al. · The Lancet · 2019 · 953 citations · Full text

Medicine, Hematology, Pharmacotherapy +14

Clinical features and prognostic factors of listeriosis: the MONALISA national prospective cohort study

Caroline Charlier, Élodie Perrodeau, Alexandre Leclercq et al. · The Lancet Infectious Diseases · 2017 · 577 citations · Full text

Life Sciences, Infectious Diseases, Microbiology +12

[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome

Corinne Haïoun, Emmanuel Itti, Alain Rahmouni et al. · Blood · 2005 · 497 citations · Full text

Medicine, Nuclear Medicine, Oncology +16